Table 1.

Conventional chemotherapy vs ASCT

Ref.YearTreatment armsOverall response (chemotherapy vs ASCT)PFS (chemotherapy vs ASCT)OS (chemotherapy vs ASCT)
Attal et al 1996 Alternating cycles of VMCP/BVAP × 18 cycles vs same regimen × 4-6 cycles followed by ASCT 57% vs 81% (P < .01) 5 y: 10% vs 28% (P = .01) 5 y: 52% vs 12% (P = .03) 
Child et al10  2003 ABCM × 4-12 cycles vs doxorubicin, cyclophosphamide, and prednisone × 3 cycles followed by ASCT CR: 8% vs 44% (P < .01) 19.6 mo vs 31.6 mo (P < .01) 42.3 mo vs 54.1 mo (P = .04) 
Bladé et al51  2005 Alternating cycles of VBMCP/VBAD followed by VBMCP/VBAD × 8 cycles vs ASCT CR: 11% vs 30% (P < .01) 33 mo vs 42 mo (P = NS) 66 mo vs 61 mo (P = NS) 
Fermand et al52  2005 VMCP until plateau vs VAMP × 3-4 cycles and ASCT CR: 20% vs 36% 19 mo vs 25 mo (P = .07) 47.6 mp vs 47.8 mo (P = .91) 
Barlogie et al11  2006 VAD × 4 cycles and VBMCP vs VAD × 4 cycles and ASCT with/without IFN maintenance  7 y: 16% vs 17% (P = NS) 7 y: 42% vs 37% (P = NS) 
Palumbo et al14  2014 RD × 4 cycles and MPR × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance  22.4 mo vs 43 mo (P < .001) 4 y: 65.3% vs 81.6% (P = .02) 
Gay et al15  2015 RD × 4 cycles and RCD × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance  28.6 mo vs 43.3 mo (P < .0001) 4 y: 73% vs 86% (P = .004) 
Ref.YearTreatment armsOverall response (chemotherapy vs ASCT)PFS (chemotherapy vs ASCT)OS (chemotherapy vs ASCT)
Attal et al 1996 Alternating cycles of VMCP/BVAP × 18 cycles vs same regimen × 4-6 cycles followed by ASCT 57% vs 81% (P < .01) 5 y: 10% vs 28% (P = .01) 5 y: 52% vs 12% (P = .03) 
Child et al10  2003 ABCM × 4-12 cycles vs doxorubicin, cyclophosphamide, and prednisone × 3 cycles followed by ASCT CR: 8% vs 44% (P < .01) 19.6 mo vs 31.6 mo (P < .01) 42.3 mo vs 54.1 mo (P = .04) 
Bladé et al51  2005 Alternating cycles of VBMCP/VBAD followed by VBMCP/VBAD × 8 cycles vs ASCT CR: 11% vs 30% (P < .01) 33 mo vs 42 mo (P = NS) 66 mo vs 61 mo (P = NS) 
Fermand et al52  2005 VMCP until plateau vs VAMP × 3-4 cycles and ASCT CR: 20% vs 36% 19 mo vs 25 mo (P = .07) 47.6 mp vs 47.8 mo (P = .91) 
Barlogie et al11  2006 VAD × 4 cycles and VBMCP vs VAD × 4 cycles and ASCT with/without IFN maintenance  7 y: 16% vs 17% (P = NS) 7 y: 42% vs 37% (P = NS) 
Palumbo et al14  2014 RD × 4 cycles and MPR × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance  22.4 mo vs 43 mo (P < .001) 4 y: 65.3% vs 81.6% (P = .02) 
Gay et al15  2015 RD × 4 cycles and RCD × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance  28.6 mo vs 43.3 mo (P < .0001) 4 y: 73% vs 86% (P = .004) 

ABCM, adriamycin; BCNU, cyclophosphamide and melphalan; BVAP, BCNU, vincristine, adriamycin, prednisone; CR, complete response; IFN, interferon; MPR, melphalan, prednisolone, Revlimid; NS, nonsignificant; R, Revlimid; RCD, Revlimid, cyclophosphamide, dexamethasone; RD, Revlimid, dexamethasone; Ref., reference; VAD, vincristine, Adriamycin, dexamethasone; VAMP, vincristine, Adriamycin, melphalan, prednisolone; VBAD, vincristine, BCNU, Adriamycin, dexamethasone; VMCP; vincristine, melphalan, cyclophosphamide, prednisolone; VBMCP, vincristine, BCNU, melphalan, cyclophosphamide, prednisolone.

or Create an Account

Close Modal
Close Modal